Dr. Dragan Grabulovski
Dr. Dragan Grabulovski is an advisor in pharmaceutical biotechnology at Grabulovski Consulting Services (CH). He was previously chief scientific officer and co-founder of Covagen AG, a Swiss biotech company acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. As Covagen’s CSO, he was responsible for developing and overseeing the execution of the overall strategy for research and development. He was a main inventor of the Fynomer technology, established a portfolio of novel bispecific FynomAb product candidates and managed the internal and collaboration pipeline. As a member of Covagen’s executive management team, Dr. Grabulovski was instrumental in Covagen’s trade sale to Johnson & Johnson, and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014 with the participation of renowned investors such as GIMV, Edmond de Rothschild Investment Partners, Novartis Venture Fund and other prestigious funds. Dr. Grabulovski received his master’s degree in pharmaceutical sciences and Doctor of Sciences from ETH Zurich (CH). He is a co-author of several peer-reviewed articles, reviews, book chapters, poster abstracts, patent applications and granted patents.